RMCH is first centre in the UK to trial an antibody as a Phase 3 study in the treatment of young patients with leukaemia
Royal Manchester Children's Hospital (RMCH) are the first team
in the UK to trial antibody, Blinatumomab, to investigate whether
it removes tumour cells in young leukaemia patients.
Consultant Paediatric Haematologist at RMCH,
Dr John Grainger is leading the study to investigate the
effectiveness, safety and tolerability of the BiTE antibody
Blinatumomab as a consolidation therapy compared to chemotherapy
treatment, for children with B-precursor Acute Lymphoblastic
Leukaemia (ALL), who have relapsed after their standard
ALL is a cancer in which the bone marrow makes too many immature
lymphocytes (a type of white blood cells) and normal blood cell
development in the marrow is reduced.
More than 200 children and teenagers in Europe, Israel and
Australia are set to take part in the trial, to determine if
Blinatumomab is safe for young patients and whether it causes any
side effects. The study will also look to see if Blinatumomab
effectively eliminates tumour cells from the body.
Dr Grainger said: "I am delighted that Manchester has been
chosen as the first UK centre to open up this new study for
patients with ALL. It is a credit to the team here that we were
selected, due to the fantastic track record of running clinical
"Blinatumomab is a type of an antibody and they help the healthy
white blood cells in the body to defend against bacteria or
viruses. They can also help attack cancer cells. The antibody acts
as a link, with one part of it binding to the surface of a cancer
cell and the other part of it binding to the surface of a healthy
white blood cell. By doing this, it helps the healthy white blood
cells to eliminate the leukemic cancer cells.
"We hope that as a result of this trial, Blinatumomab will
demonstrate a reduction in the risk of relapse for young patients,
and increase chances of achieving a complete remission at the end